A 28-day PDRN eye-cream comparison reported favorable instrument readings. Its design leaves lasting collagen effects unresolved.
A review published on November 1, 2026 assessed a PDRN-850K eye-cream study that reported favorable short-term wrinkle and elasticity measurements compared with retinol. The underlying paper by Rui Ye and colleagues appeared in PLOS ONE in July 2026. It combined laboratory research and skin-model work with a human split-face comparison.
The finding offers a specific result to examine amid attention to PDRN skincare. Its most useful contribution is a comparison between two tested eye creams, with instrument readings that deserve careful interpretation.
According to coverage of the study, the researchers reported more favorable short-term instrumental wrinkle and elasticity outcomes for the tested PDRN-850K cream than for the retinol comparator. They also reported improvements across several other measured outcomes.
The clinical comparison concerned an eye-area formulation containing a particular PDRN preparation. That formulation is the subject of the finding, rather than PDRN skincare as a whole.
The paper also examined extracellular-matrix proteins, including collagens, through laboratory and ex vivo skin-model work. This gives the research both a biological component and a cosmetic-testing component. The biological work asks questions about matrix-related processes, while the human comparison tracks changes measured around the eyes.
For readers interested in collagen, keeping those parts of the paper distinct is essential. A laboratory result and a human skin measurement answer different questions, even when they appear in the same publication.
The study coverage describes the clinical comparison as follows:
This split-face format placed both products within the same participants. The comparison was therefore between the two treated sides, rather than between entirely separate groups of users.
The authors reported roughly twice the improvement in measured elasticity, firmness, dermal thickness and density. They also reported roughly twice the improvement in eye-bag or tear-trough measures. The wrinkle findings were described as more favorable for the PDRN-treated side.
Those are instrumental outcomes. A relative advantage in a measurement does not by itself describe how noticeable a change was to the person using the cream. Controlled study readings also should not be treated as a forecast of everyday results.
The November review notes that the study included an active retinol comparator but no vehicle-only arm. A vehicle is the formulation base without the ingredient being evaluated. Without that comparison, the trial cannot fully separate PDRN's contribution from other effects of the cream.
This matters when moving from a product result to an ingredient claim. The tested formula produced the reported measurements, but the design does not establish how much of the difference came from PDRN itself.
The small participant group and short follow-up make the findings preliminary. The review also flags a specific interpretation problem: early changes in structural measurements may partly reflect hydration or plumping. Longer observation would help distinguish those effects from sustained dermal remodeling.
The laboratory and skin-model findings do not fill that clinical gap. They are not evidence that the participants experienced durable collagen rebuilding. Results from this eye-area formula also do not establish that other PDRN products outperform retinol, or that findings transfer to other concentrations or facial areas.
Several authors had affiliations with skincare-related biotechnology companies, according to the review. The paper also reported a declaration of no conflicts. Both details belong in an account of the study.
Affiliations alone do not invalidate a result. They are relevant context when weighing a favorable product comparison and considering the value of independent follow-up.
The paper included exploratory delivery work using Raman measurements. The review notes that this method cannot unequivocally distinguish added PDRN from the skin's own nucleic acids. That limits confidence in the interpretation of penetration findings.
The authors reported that both creams were well tolerated and that no adverse reactions occurred during the trial. This describes the experience of the participants during the comparison. It does not establish long-term safety or tolerability across a broader population.
For someone evaluating an eye cream, the practical distinction is between evidence for a finished product and enthusiasm for an ingredient category. This study supports a discussion of the tested PDRN-850K formulation. It is not a reason to assume that any cream displaying PDRN on its label has equivalent evidence.
A useful way to read related marketing is to keep three questions in view:
These are questions about the evidence, not instructions to change a routine. Personal decisions about eye-area products or skin sensitivity are best discussed with a qualified clinician.
Younell's broader discussion of the evidence behind topical PDRN provides context for reading claims in this category. Our examination of clinical research on topical peptides offers another place to consider how closely product language follows the research being cited.
The next useful research would address whether the measured advantage persists and how much the ingredient contributes beyond its formulation base. Independent comparisons would also help establish whether the reported pattern is reproducible.
For now, the most defensible takeaway is specific: researchers reported favorable short-term instrumental outcomes for one PDRN-850K eye cream against one retinol comparator. That is a finding worth following, with its significance still tied to the design and measurements of this trial.
Stay connected for research and practical guidance on skin, hair, collagen, nutrition and beauty longevity. Clear ideas for people who want to understand how appearance changes with age and make better-informed choices over time.
Understand your skin, hair and body better without chasing every new trend, treatment or promise.
explore the Blog
